Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 23 07 2018
accepted: 03 09 2018
pubmed: 16 9 2018
medline: 21 5 2019
entrez: 16 9 2018
Statut: ppublish

Résumé

We report cases of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) with trisomy 8 associated with inflammatory and autoimmune diseases (IADs). Data for 21 patients with trisomy 8-MDS/MPN and IADs were analyzed and compared to 103 patients with trisomy 8-MDS/MPN without IADs. The median age of MDS/MPN patients with IADs was 67 [59-80]. The IADs were Behçet's-like disease in 11 (52%) patients, inflammatory arthritis in 4 (19%) and Sjögren's syndrome, autoimmune hemolytic anemia, aseptic abscess, periarteritis nodosa, Sweet's syndrome and unclassified vasculitis in one patient each. Overall, 17/21 (81%) patients with IADs received treatment (88% with steroids), with complete and partial response in 7/17 (35%) and 8/17 (47%), respectively. The effect of MDS treatment on IADs could be assessed in seven patients receiving azacytidine: five achieved remission and two partial response. As compared with the 103 trisomy 8-MDS/MPN cases without IADs, those with IADs were more often non-European (P = 0.005) and had poor karyotype (P < 0.001). We found no difference in overall survival or acute myeloid leukemia progression between trisomy 8-associated MDS/MPN with and without IADs. The spectrum of IADs associated with trisomy 8-positive MDS/MPN is dominated by Behçet's-like disease. Steroid therapy is effective, but mostly sparing therapies are necessary. Azacytidine could be an effective alternative.

Identifiants

pubmed: 30218579
doi: 10.1111/ejh.13174
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

63-69

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Nadege Wesner (N)

Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
Sorbonne Universités, F-75012 Paris, France.
INSERM U938, Centre de Recherche Saint-Antoine (CRSA), UMPC University Paris 06, Sorbonne Universités, Paris, France.

Louis Drevon (L)

Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
Sorbonne Universités, F-75012 Paris, France.
INSERM U938, Centre de Recherche Saint-Antoine (CRSA), UMPC University Paris 06, Sorbonne Universités, Paris, France.

Alexis Guedon (A)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Sorbonne Université, Paris, France.

Jean Baptiste Fraison (JB)

Department of Internal Medicine, Hôpital Sète, Sète, France.

Salim Trad (S)

Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France.

Jean Emmanuel Kahn (JE)

Department of Internal Medicine, Hôpital Foch, Suresnes, France.

Achille Aouba (A)

Department of Internal Medicine, CH Caen, Caen, France.

Jerome Gillard (J)

Department of Rheumatology, CH Lons le Saunier, Lons le Saunier, France.

Matthieu Ponsoye (M)

Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France.

Thomas Hanslik (T)

Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France.

Clement Gourguechon (C)

Department of Internal Medicine, CHU Amiens-Picardie, Amiens, France.

Eric Liozon (E)

Department of Internal Medicine, CHU Limoges, Limoges, France.

Kamel Laribi (K)

Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France.

Julien Rossignol (J)

Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris, France.

Olivier Hermine (O)

Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Paris, France.

Lionel Adès (L)

Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, France.

Fabrice Carrat (F)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Sorbonne Université, Paris, France.

Pierre Fenaux (P)

INSERM U938, Centre de Recherche Saint-Antoine (CRSA), UMPC University Paris 06, Sorbonne Universités, Paris, France.

Arsene Mekinian (A)

Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
Sorbonne Universités, F-75012 Paris, France.

Olivier Fain (O)

Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
Sorbonne Universités, F-75012 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH